Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Drugs Have The Worst Phase III Track Record, BIO Study Shows

This article was originally published in The Pink Sheet Daily

Executive Summary

New data indicating that only one-third of oncologic agents succeed in Phase III, coupled with tougher regulatory hurdles ahead, could give big pharma and investors pause before committing resources in the therapeutic category.

You may also be interested in...



New Drugs Build On Personalized Medicine Momentum In Lung Cancer

Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.

ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up

Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.

ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up

After a progression-free survival benefit failed to translate into overall survival in a Phase III NSCLC study of ArQule/Daiichi Sankyo’s c-Met inhibitor tivantinib, ArQule is shifting focus to an imminent, targeted second-line Phase III study in high-Met expressing hepatocellular cancer.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel